Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Genitourinary Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1493922

Tumor-shrinking Effects of Enfortumab Vedotin between Primary Urothelial Carcinoma and Metastatic Organs

Provisionally accepted
Daiki Ikarashi Daiki Ikarashi *Tatsuya Kawamura Tatsuya Kawamura Keita Ogasawara Keita Ogasawara Yumeka Arakawa Yumeka Arakawa Arisa Machida Arisa Machida Ayato Ito Ayato Ito Ei Shiomi Ei Shiomi Shigekatsu Maekawa Shigekatsu Maekawa Renpei Kato Renpei Kato Mitsugu Kanehira Mitsugu Kanehira Jun Sugimura Jun Sugimura Wataru Obara Wataru Obara
  • Iwate Medical University, Morioka, Japan

The final, formatted version of the article will be published soon.

    This study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.We retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedotin for advanced urothelial carcinoma. We also evaluated the periods of tumor shrinkage maintenance (the period when best response was maintained) and regrowth (the period from best response to tumor growth confirmation) between primary and metastatic organs.Measurable metastatic organs included the lung in 17, lymph node in 22, liver in 6, and bone in 5 cases. Primary lesion was detected in 20 cases. The mean tumor shrinkage rates for lung, lymph node, liver, and bone metastases and primary sites were 21% (-212 to 100), 13% (-130 to 86), -8.5% (-158 to 85), -64% (-250 to 21), and 22% (-38 to 79), respectively. The tumor shrinkage was maintained for 5.9 (0.7-14) months in lung metastases, 8.3 (2.6-14.5) months in lymph node metastases, 3.6 months in liver metastases, 0.7 months in bone metastases, and 1.8 (0.7-5.4) months in primary sites, and the period of regrowth was 7.3 (2.2-19.4), 4.8 (2.0-8.9), 2.8, 6.5, and 2.5 (1.1-5.9) months, respectively.Enfortumab vedotin showed significant tumor shrinkage in the primary tumor, lung metastases, and lymph node metastases, whereas the durability of tumor shrinkage was limited in the primary tumor.

    Keywords: durability, Enfortmab vedotin, primary, Metastatic organ, Tumor shrinkage

    Received: 10 Sep 2024; Accepted: 31 Dec 2024.

    Copyright: © 2024 Ikarashi, Kawamura, Ogasawara, Arakawa, Machida, Ito, Shiomi, Maekawa, Kato, Kanehira, Sugimura and Obara. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Daiki Ikarashi, Iwate Medical University, Morioka, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.